Diagnostic Approach for Hemorrhagic or Complex Ovarian Cysts

Primary Diagnostic Approach

The American College of Radiology recommends transvaginal ultrasound with grayscale morphologic assessment as the gold standard for evaluating hemorrhagic and complex cysts, as it directly visualizes cyst characteristics that determine malignancy risk 1, 2
Ultrasound is superior to CA-125 in distinguishing benign from malignant ovarian lesions, with CA-125 performing worse than ultrasound alone in multiple studies 1, 2
The inclusion of color or power Doppler in the ultrasound examination is crucial to differentiate true solid components from hemorrhagic debris within complex cysts, which is critical for accurate diagnosis 1, 2, 3

CA-125 has only 50% sensitivity for early-stage ovarian cancer, meaning it misses half of early malignancies even when present 4, 3
CA-125 is frequently elevated in benign conditions, including endometriosis, adenomyosis, pelvic inflammatory disease, and functional hemorrhagic cysts, which can cause false-positive results 4, 3
CA-125 may be low or normal in low-grade malignancies and borderline tumors, which can present as complex cysts 1, 2

The American College of Radiology suggests that CA-125 can help stratify malignancy risk when ultrasound shows indeterminate or suspicious features, but it should not be used as a standalone test 1, 2, 4
Serial CA-125 measurements showing progressive elevation over time are more concerning than single values, as malignancies demonstrate rising trends 5, 3, 6
A standard cutoff of 35 U/mL has 98.5% specificity in postmenopausal women but poor sensitivity for early disease 4, 3

The diagnostic algorithm should start with a comprehensive ultrasound evaluation, including transvaginal ultrasound with both grayscale and color/power Doppler, to assess cyst morphology and vascularity patterns 1, 2, 3
The American College of Radiology recommends applying IOTA Simple Rules or O-RADS classification to stratify malignancy risk based on morphologic features 4, 3
CA-125 should only be ordered if ultrasound shows indeterminate or suspicious features that suggest possible malignancy 1, 2, 3

The American College of Radiology advises against using CA-125 as a screening or standalone diagnostic test for hemorrhagic or complex cysts, as this leads to false reassurance when normal and unnecessary anxiety/intervention when elevated 1, 2, 3
Elevated CA-125 should not be interpreted as diagnostic of malignancy without correlating with ultrasound morphology, as benign conditions frequently cause elevation 4, 3
A single normal CA-125 value should not be relied upon to exclude malignancy in a complex cyst with suspicious ultrasound features, given the 50% false-negative rate in early-stage disease 4, 3

The American College of Radiology recommends using the O-RADS classification system to stratify malignancy risk based on morphologic features, and CA-125 testing should be considered in postmenopausal women with O-RADS 4 lesions (10-50% malignancy risk) 7
The American College of Radiology suggests that CA-125 testing is useful in determining the need for gynecologic oncology referral in postmenopausal women with O-RADS 4 lesions, and in surgical planning for O-RADS 5 lesions (50-100% malignancy risk) 7
A normal CA-125 does not exclude malignancy in a postmenopausal woman with suspicious ultrasound features (O-RADS 4 or 5), according to the American College of Radiology 7
The American College of Radiology recommends that CA-125 testing be considered in postmenopausal women with complex morphology on ultrasound, including solid components, papillary projections, or thick septations 7

The American College of Radiology recommends that ultrasound morphology takes precedence over CA-125 levels in determining management, and suspicious features warrant referral even with normal CA-125 7

CA‑125 improves specificity only for ovarian lesions that are already suspected to be malignant on transvaginal ultrasound, and does not add diagnostic value for general mass evaluation. 8

The IOTA Simple Rules demonstrate a sensitivity of 0.93 and a specificity of 0.81 for predicting malignancy in ovarian masses. 8
Benign (IOTA B) ultrasound features include: unilocular cyst, solid components < 7 mm, acoustic shadows, smooth multilocular tumor, maximum diameter < 100 mm, and absent Doppler flow. 8
Malignant (IOTA M) ultrasound features include: irregular solid tumor, presence of ascites, ≥ 4 papillary projections, irregular multilocular‑solid tumor, diameter ≥ 100 mm, and very strong Doppler flow. 8

In postmenopausal patients, an elevated CA‑125 > 35 U/mL together with any of the following ultrasound findings—nodular or fixed pelvic mass, complex morphology (solid components, papillary projections, or thick septations), O‑RADS 4 (10‑50 % malignancy risk), or O‑RADS 5 (50‑100 % risk)—warrants referral to gynecologic oncology. 9
The ACOG/SGO criteria specifically recommend referral for postmenopausal women who have an elevated CA‑125 combined with concerning clinical or imaging features. 9

For premenopausal patients, a CA‑125 level > 200 U/mL (some experts suggest a lower threshold of > 50 U/mL) triggers referral to gynecologic oncology according to ACOG/SGO guidance. 9
Referral is also advised when any of the following are present: ultrasound shows indeterminate or suspicious features, there is metastatic disease or ascites, or the patient has a strong family history of breast or ovarian cancer. 9

When CA‑125 is elevated and ultrasound demonstrates suspicious features, the combined risk is considered high, and immediate referral to a gynecologic oncology specialist is recommended. 9